Featured Research

from universities, journals, and other organizations

Phase II trial of efatutazone shows challenge of matching treatment to population

Date:
April 8, 2014
Source:
University of Colorado Denver
Summary:
A phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer produced results that suggested that while efatutazone did not improve the efficacy of erlotinib, there is hope that lessons from the trial will allow researchers to make better future use of the drug or other drugs in its class.

Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported at the American Association for Cancer Research (AACR) Annual Meeting 2014. While efatutazone did not improve the efficacy of erlotinib in this trial, researchers hope lessons from the trial will allow them to make better future use of the drug or other drugs in its class.

Related Articles


"In oncology and especially in lung cancer, everything is personalized. We're exploring different molecular markers that identify which drugs are for the right patient After this phase II trial, we're working to find the right biomarker that could help us discover who is most likely to respond to efatutazone. This trial was done in an unselected population. But if we had the right population with the right marker, we hope that we could find a meaningful effect," says Ana Oton, MD, investigator at the CU Cancer Center, Associate Professor of Medical Oncology at the University of Colorado School of Medicine, and the study's first author.

Efatutazone belongs to a class of drugs known as thiazolidinediones, members of which are currently in use for the treatment of type II diabetes. Drugs in this class influence the expression of cell proteins by binding to the nuclear receptor PPARy. In diabetes, the drugs increase the production of proteins that drive metabolism. In cancer, the drug showed anti-cancer activity in preclinical models of non-small cell lung cancer. A phase I trial the drug alone showed anti-cancer activity in patients with solid malignancies.

The current, multi-center study compared efatutazone with erlotinib versus erlotinib alone in 90 patients previously treated for non-small cell lung cancer. Unfortunately, Oton explains, "In vitro it looked really promising, but in vivo it was not so good."

The majority of the difference between success in the lab and lack of success in patients was due to the side effect of fluid retention.

"Fluid retention in lower extremities is a side effect that can be easily managed," Oton says, "however, if this fluid retention is in the pleural space in patients that have already metastatic lung cancer, it can be very detrimental."

"We're not denying this combination could be useful, but with the knowledge we have we shouldn't do more studies in vivo at this time. We need to determine what patient population will be best served and second, discover how to manage this side-effect" Oton says.


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Cite This Page:

University of Colorado Denver. "Phase II trial of efatutazone shows challenge of matching treatment to population." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408122131.htm>.
University of Colorado Denver. (2014, April 8). Phase II trial of efatutazone shows challenge of matching treatment to population. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2014/04/140408122131.htm
University of Colorado Denver. "Phase II trial of efatutazone shows challenge of matching treatment to population." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408122131.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins